Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Follow us on LinkedIn ... available in abundance in nature. These natural bio-based ... as shells of crustaceans. The significant commercial interest ... the high percentage of nitrogen present compared to ... industries owing to its exclusive properties such as ...
(Date:9/22/2014)... Invisible Sentinel Inc., a life-sciences company ... beverage industries, announced today that its first-in-class Veriflow® ... agreement by Enartis, a global provider of specialty ... Group company headquartered in Trecate, Italy, will distribute ... global markets for their own in-winery use in ...
(Date:9/22/2014)... September 22, 2014 FierceBiotech today announced ... held biotechnology companies of 2014. FierceBiotech editors John ... selecting this year’s winners. Those selected are identified ... in the industry. , "It's always a ... of Fierce 15 companies," said Carroll. "This year in ...
(Date:9/22/2014)... Olso, Norway (PRWEB) September 22, 2014 ... convenient new parcel and pallet measuring device ... ScanTape™ eliminates manual data entry, offering greater ease ... time savings that result can significantly enhance productivity—an ... in industries where processing volume equals profits. ...
Breaking Biology Technology:Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2ScanTape™ Handheld Dimensioner Increases Processing Volume 2
... occasion of World Kidney Day, Kibow Biotech, Inc. is ... for the worldwide maintenance of healthy kidney function among ... In addition, Kibow Biotech, Inc. would also like to ... approvals for conducting human clinical trials with its patented, ...
... brain is a black box. A complex circuitry of ... workings of a computer chip. But while computer processors ... line, neural circuits are impenetrable masses. Think tumbleweed. ... developed a technique for unraveling these masses. Through a ...
... Colo.Physicists at the National,Institute of Standards and ... microwaves communicate with,a vibrating mechanical component 1,000 ... experiments. The microscopic,apparatus is a new tool ... of a relatively large object at the,smallest ...
Cached Biology Technology:Institutional Review Board Approval Obtained for Study of Kibow(R) Biotics in Dialysis Patients with End-stage Chronic Kidney Disease 2Institutional Review Board Approval Obtained for Study of Kibow(R) Biotics in Dialysis Patients with End-stage Chronic Kidney Disease 3Web-crawling the brain 2Web-crawling the brain 3NIST electromechanical circuit sets record beating microscopic 'drum' 2NIST electromechanical circuit sets record beating microscopic 'drum' 3
(Date:9/21/2014)... the University of California, San Diego, have developed a ... control the activity of genes based on sequences of ... its application to human embryonic cells in a paper ... , "All of our cells have the same blueprint, ... John Whitaker, lead author of the report. "Skin cells ...
(Date:9/19/2014)... it the Jimmy Durante of dinosaurs a ... profile. The new dinosaur, named Rhinorex condrupus ... and Brigham Young University, lived in what is ... the Late Cretaceous period. , Rhinorex, which translates ... a close relative of other Cretaceous hadrosaurs like ...
(Date:9/19/2014)... are a species which over thousands of years has adapted ... a substance that makes the cold dangerous for you. , ... albidus , and the cold provoking substance, called nonylphenol, comes ... Nonylphenol is suspected of being a endocrine disruptor, but when ... the worm,s ability to protect the cells in its body ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... Efforts to understand how the aging process affects the ... and older adults. "Everybody ages differently. By looking ... vascular health, we begin to understand that preventable factors ... State University psychology doctoral student Andrew Bender, lead author ...
... London have found a new therapeutic target to combat ... Cellular and Molecular Life Sciences , revealed tiny organelles ... findings could lead to potential therapies for millions of ... Knight who led the research at Queen Mary,s School ...
... 2012 Researchers at the Institute of Bioengineering and ... institute, have developed a miniaturized biochip for investigating the ... recently in Nano Today , this new technology ... In a tumor, CSCs form a small and ...
Cached Biology News:WSU researchers say genes and vascular risk modify effects of aging on brain and cognition 2WSU researchers say genes and vascular risk modify effects of aging on brain and cognition 3IBN's Droplet Array sheds light on drug-resistant cancer stem cells 2IBN's Droplet Array sheds light on drug-resistant cancer stem cells 3
Purified anti-LAT...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Biology Products: